whalesbook.com
Cure8 news brief
Why This Matters
An FDA approval for an autoinjector of a biosimilar ustekinumab can make treatment easier to administer and may increase availability or affordability of a drug used to treat Crohn’s disease and ulcerative colitis. Patients on or considering ustekinumab might gain a new device option.
Who Should Pay Attention
Adult patients with Crohn’s disease or ulcerative colitis who are using or may use ustekinumab; clinicians who prescribe biologics; pharmacists and payors tracking biosimilar availability.
Study Snapshot
Story typeBusiness news
Evidence typeRegulatory update
Source depthFull source text
What To Know
FDA granted supplemental approval for Biocon’s Yesintek (ustekinumab-kfce) in a single‑dose prefilled autoinjector available in two strengths (45 mg/0.5 ml and 90 mg/ml).
The approval expands delivery options for the biosimilar previously approved in 2024 and lists indications that include plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
This article is a brief corporate news report about the regulatory milestone and commercial implications; it does not present clinical trial data or new efficacy/safety findings.
The key practical change is that Yesintek can now be marketed in an autoinjector format in the U.S., which may affect patient convenience, prescribing choices, and market access for a biosimilar ustekinumab product.
If you use or prescribe ustekinumab, device availability and strength options may be relevant to administration preferences or insurance coverage, but specific clinical or coverage decisions should be discussed with your care team or pharmacist.
Keep In Mind
This is a regulatory approval/format change reported by a corporate news source; the article summarizes the approval and commercial implications but does not provide new clinical safety or efficacy data. Availability, insurance coverage, or formulary decisions will determine patient access in practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationwhalesbook.com
AuthorsKavya Nair
Indexed viaGoogle News
Source typeWeb article
PublishedAug 18, 2026, 10:03 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva jumps on FDA approval for biosimilar
An FDA interchangeability approval for a biosimilar to ustekinumab could make a lower-cost alternative more available for people with Crohn’s disease or ulcerative colitis who use Stelara. It’s primarily a regulatory and...
Biocon: US FDA Approves Yesintek Single-Dose Autoinjector - InvestyWise
An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...
Biocon Biologics launches Yesintek biosimilar to Stelara in US
A new FDA‑approved biosimilar to ustekinumab is now available in the U.S., which may increase treatment options and lower out‑of‑pocket costs for people with Crohn’s disease or ulcerative colitis. The article highlights...